Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025
Edgewise Therapeutics (NASDAQ: EWTX), a muscle disease biopharmaceutical company, has announced its upcoming participation in the RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for Tuesday, May 20, 2025, at 9:00 am ET. The event will feature a live webcast accessible through the company's Events & Presentations page, with replay availability for a limited time after the conference. Attendees are advised to connect several minutes before the start time to ensure proper connection.
Edgewise Therapeutics (NASDAQ: EWTX), un'azienda biofarmaceutica specializzata nelle malattie muscolari, ha annunciato la sua partecipazione al RBC Capital Markets Global Healthcare Conference. La presentazione è prevista per martedì 20 maggio 2025 alle 9:00 ET. L'evento sarà trasmesso in diretta streaming, accessibile tramite la pagina Eventi e Presentazioni della società, con la possibilità di rivedere la registrazione per un periodo limitato dopo la conferenza. Si consiglia ai partecipanti di collegarsi qualche minuto prima dell'inizio per assicurarsi una connessione stabile.
Edgewise Therapeutics (NASDAQ: EWTX), una compañía biofarmacéutica especializada en enfermedades musculares, ha anunciado su próxima participación en la RBC Capital Markets Global Healthcare Conference. La presentación está programada para el martes 20 de mayo de 2025 a las 9:00 am ET. El evento contará con una transmisión en vivo accesible a través de la página de Eventos y Presentaciones de la empresa, con disponibilidad de repetición por un tiempo limitado después de la conferencia. Se recomienda a los asistentes conectarse varios minutos antes del inicio para asegurar una conexión adecuada.
Edgewise Therapeutics (NASDAQ: EWTX)는 근육 질환 바이오제약 회사로, RBC Capital Markets Global Healthcare Conference에 참여할 예정임을 발표했습니다. 발표는 2025년 5월 20일 화요일 오전 9시(동부시간)에 예정되어 있습니다. 이 행사는 회사의 이벤트 및 프레젠테이션 페이지를 통해 실시간 웹캐스트로 제공되며, 회의 종료 후 제한된 기간 동안 다시보기 서비스도 제공됩니다. 참석자들은 원활한 접속을 위해 시작 시간 몇 분 전에 접속할 것을 권장합니다.
Edgewise Therapeutics (NASDAQ : EWTX), une société biopharmaceutique spécialisée dans les maladies musculaires, a annoncé sa prochaine participation à la RBC Capital Markets Global Healthcare Conference. La présentation est prévue pour le mardi 20 mai 2025 à 9h00 ET. L'événement sera diffusé en direct via la page Événements et Présentations de la société, avec une rediffusion disponible pendant une durée limitée après la conférence. Il est conseillé aux participants de se connecter quelques minutes avant le début afin d'assurer une connexion optimale.
Edgewise Therapeutics (NASDAQ: EWTX), ein biopharmazeutisches Unternehmen für Muskelerkrankungen, hat seine bevorstehende Teilnahme an der RBC Capital Markets Global Healthcare Conference angekündigt. Die Präsentation ist für Dienstag, den 20. Mai 2025, um 9:00 Uhr ET geplant. Die Veranstaltung wird als Live-Webcast über die Seite für Veranstaltungen und Präsentationen des Unternehmens zugänglich sein, mit einer begrenzten Zeitspanne für die Wiedergabe nach der Konferenz. Den Teilnehmern wird empfohlen, sich einige Minuten vor Beginn einzuwählen, um eine stabile Verbindung sicherzustellen.
- None.
- None.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-rbc-capital-markets-global-healthcare-conference-on-may-20-2025-302452775.html
SOURCE Edgewise Therapeutics
FAQ
When is Edgewise Therapeutics (EWTX) presenting at the RBC Capital Markets Healthcare Conference?
How can investors access Edgewise Therapeutics' (EWTX) RBC Conference presentation?
What type of company is Edgewise Therapeutics (EWTX)?
Where can I find the webcast link for EWTX's RBC Conference presentation?
